Sumanta Pal: Meet the Experts of VIRO 2025

The Global Voices in Renal Oncology (VIRO) Virtual Congress, organized by OncoDaily, will be held on September 11–12, 2025. Chaired by Dr. Rana R. McKay with co-chair Dr. Yüksel Ürün, this year’s program will feature around 50 leading experts in renal oncology from across the globe, sharing cutting-edge updates and future perspectives.

• The congress is free to attend.
• Register via the link.

Co-Chair of VIRO

Images

Name

Rana McKay Professor of Medicine and Urology at UC San Diego Health Co-leader of the GU Oncology Program at Moores Cancer Center As Co-Chair of VIRO, Dr. Rana McKay (University of California, San Diego) opened the congress with her talk on  “Future Directions: Emerging Agents and Combinations.” She emphasized the momentum in renal cell carcinoma (RCC) research, highlighting how novel immunotherapies, targeted drugs, and rational combination strategies are reshaping patient care. Dr. McKay underscored the importance of personalized, biomarker-driven approaches and global collaboration, aiming to optimize survival and quality of life worldwide.

Spotlight on Sumanta Pal

Dr. Sumanta Pal is Professor and Vice Chair of Academic Affairs at City of Hope, Chair of the Kidney and Bladder Cancer Disease Team, and Co-director of the Kidney Cancer Program. His clinical expertise and research focus on advancing the diagnosis and treatment of renal cell carcinoma, with a particular interest in variant histologies.

At the Global Voices in Renal Oncology (VIRO) Virtual Congress 2025, Dr. Pal will present on “Papillary RCC: Diagnosis and Treatment”. His presentation will highlight:

• Key diagnostic challenges and criteria specific to papillary renal cell carcinoma.
• Current therapeutic strategies and emerging treatments tailored for papillary RCC.
• Insights into the biological and molecular characteristics influencing treatment outcomes.
• Strategies to optimize patient care and improve prognosis in this RCC variant.

Dr. Pal’s extensive research and clinical experience highlight the importance of personalized and integrative management approaches for papillary RCC, aiming to enhance patient outcomes through innovation and multidisciplinary collaboration.

Global Voices in Renal Oncology (VIRO) 2025